Clinical Trials Logo

Adenocarcinoma clinical trials

View clinical trials related to Adenocarcinoma.

Filter by:

NCT ID: NCT04145297 Completed - Clinical trials for Gastrointestinal Neoplasms

Ulixertinib (BVD-523) and Hydroxychloroquine in Patients w Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas

UTAH
Start date: March 17, 2020
Phase: Phase 1
Study type: Interventional

Open-label dose escalation of Ulixertinib combined with fixed dose of hydroxychloroquine.

NCT ID: NCT04144010 Recruiting - Clinical trials for Prostate Adenocarcinoma

Gallium-68 PSMA-11 PET/CT for the Diagnosis of Biochemically Recurrent Prostate Cancer

Start date: December 1, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well gallium-68 PSMA-11 PET/CT works for the diagnosis of prostate cancer with rising PSA following prostatectomy or radiation therapy (biochemically recurrent). Gallium-68 PSMA-11 is a radioactive tracer. PET/CT scans reveal information about both the structure and function of cells and tissues in the body during a single imaging session using a radioactive compound. This trial is being done to see if gallium-68 PSMA-11 PET/CT scan works better in diagnosing prostate cancer compared to standard C-11 choline PET/CT scans.

NCT ID: NCT04141566 Completed - Quality of Life Clinical Trials

Pseudo Continent Perineal Colostomy vs Permanent Left Iliac Colostomy After Abdominoperineal Resection for Ultra Low Rectal Adenocarcinoma

Start date: January 1, 2018
Phase:
Study type: Observational

Aim of this study is to compare the cost-effectiveness and the quality of life in the 6 months following the surgery of a pseudo continent perineal colostomy (PCPC) and a permanent left iliac colostomy (PLIC) following an abdominoperineal resection (APR) for ultra low rectal cancer

NCT ID: NCT04140318 Recruiting - Clinical trials for Advanced Gastric and Gastro-esophageal Junction Adenocarcinoma

Sintilimab and Nab-paclitaxel in Second-line Treatment of Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma

Start date: November 15, 2019
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of Sintilimab (PD-1 inhibitor) and nab-paclitaxel in second line treatment of advanced gastric and gastro-esophageal junction adenocarcinoma. This is a prospective, multi-centers, single arm phase II trial with primary objective overall response rate and second objective of safety and other efficacy endpoints.

NCT ID: NCT04134468 Withdrawn - Clinical trials for Pancreatic Ductal Adenocarcinoma

MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma

Start date: January 2020
Phase: Phase 2
Study type: Interventional

This research study is being conducted to determine the effects of PEGPH20 plus chemotherapy treatment on the MRI characteristics of locally advanced pancreatic cancer patient tumors. Subjects will received Gemcitabine, Abraxane and PEGPH20.

NCT ID: NCT04130854 Active, not recruiting - Clinical trials for Locally Advanced Rectal Adenocarcinoma

INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer

Start date: April 24, 2020
Phase: Phase 2
Study type: Interventional

Determine the complete pathologic complete response (pCR) rate in patients with locally advanced rectal adenocarcinoma.

NCT ID: NCT04130399 Withdrawn - Pancreatic Cancer Clinical Trials

Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer

Start date: July 1, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to research the effects of delivering full-dose neoadjuvant multi-agent chemotherapy (folfirinox) followed by stereotactic body radiation therapy (SBRT) in patients with resectable pancreatic ductal adenocarcinoma (PDAC) in order to intensify local therapy and improve outcomes.

NCT ID: NCT04126070 Active, not recruiting - Clinical trials for Prostate Adenocarcinoma

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Start date: May 11, 2020
Phase: Phase 2
Study type: Interventional

This research study is studying a combination of hormonal therapy, chemotherapy, and immunotherapy as a possible treatment for metastatic hormone-sensitive prostate cancer. The names of the study drugs involved in this study are: - Androgen deprivation therapy (ADT) with a drug of your physician's choice. This may include leuprolide (Lupron), goserelin acetate (Zoladex), or degarelix (Firmagon). - Docetaxel - Nivolumab

NCT ID: NCT04122833 Recruiting - Clinical trials for Adenocarcinoma of Lung

Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study

Start date: September 30, 2019
Phase:
Study type: Observational

The concomitant co-mutation with epidermal growth factor receptor (EGFR) mutation might influence the clinical outcomes. The investigators will identify the impact of concommitant mutation on clinical outcome in patients with advanced -EGFR mutated adenocarcinoma. The investigators will compare the genetic alterations between tumors of pre and post Tyrosin Kinase Inhibitor(TKI) treatments and predict the resistance mechanism for EGFR-TKIs by next-generation sequencing(NGS) analysis.

NCT ID: NCT04121039 Not yet recruiting - Advanced Cancer Clinical Trials

Study of the Apatinib Combine With POF Versus POF in Gastric Cancer

Start date: December 2019
Phase: Phase 2
Study type: Interventional

This study is a randomized, parallel control, multicenter,phase II study, comparing the efficacy and safety of apatinib plus POF(paclitaxel plus oxaliplatin plus 5-fluorouracil plus leucovorin) versus POF, in the first-line treatment for patients with advanced/metastatic gastric cancer.